Durvalumab cost effective in unresectable stage III NSCLC.

"This research reinforces the considerable patient benefit observed with durvalumab and supports the use of this cost-effective therapy... It also provides an informative case study on cost-effectiveness analyses in the unresectable stage III NSCLC setting from both methodological and policy perspectives", concluded the authors. A semi-Markov model populated with 4-year survival data from the phase III PACIFIC study was used to validate survival extrapolations used in the AstraZeneca base-case analysis which evaluated the cost effectiveness of durvalumab versus placebo in patients with unresectable stage III NSCLC. Treatment with durvalumab is cost effective in patients with unresectable stage III non-small cell lung cancer (NSCLC), according to findings of an AstraZeneca-funded study published in I PharmacoEconomics i . [Extracted from the article]